The latest -Cancer Diagnostic Testing World Markets -Report By Aarkstore

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) January 23, 2012 -- Cancer Diagnostic Testing World Markets

http://www.emarketreports.com/reports/Cancer-Diagnostic-Testing-World-Markets-1303.html

Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position.

Table of Contents :

1. Overview 8

1.1 Statement of Report 8

1.2 About This Report 8

1.3 Scope of the Report 9

1.4 Objectives 10

1.5 Methodology 10

1.6 Executive Summary 11

2. Introduction to Cancer Biology and the Diagnostic Industry 14

2.1 Cancer 14

2.1.1 The Disease 14

2.1.2 Metastasis 14

2.1.3 Demographics and Statistics of Cancer 14

3. Tumor Markers Market Segment Analysis: Size, Growth and Share 23

3.1 Market Description 24

3.2 Clinical Diagnostic Serum Based Cancer Markers 31

3.3 PSA Testing Market Size 32

3.4 DNA Markers 33

3.5 Serum Proteins 33

4. Diagnostic Methods for Cancer Detection 59

4.1 Organ Specific Tumor Markers 59

4.1.1 Colon Cancer 59

4.1.2 Prostate Cancer 66

4.1.3 Pancreatic Cancer 83

4.1.4 Breast Cancer 85

5. Implications of Molecular Biology for New Diagnostic Cancer Tests 145

6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 146

6.1 Abbott Diagnostics 146

6.2 Affymetrix, Inc. 147

6.3 Agendia BV 148

6.4 Agensys, Inc. 148

6.5 Ambrilla Biopharma, Inc. 149

6.6 AMDL, Inc. 149

7. Business Trends in the Industry 201

7.1 Industry Consolidation 201

7.2 Breadth of Product Offering and Pricing 201

7.3 Government Regulation of Medical Devices 202

7.4 Strategic Business and Marketing Considerations 203

7.5 Commercial Opportunities in Cancer Markers 204

8. Tumor Marker Testing: Important Issues 215

8.1 Trends in Patient Care and Reimbursement 215

8.2 Trends in Reimbursement Practice 216

9. Important New Technology Areas 220

9.1 Proteins 220

9.2 DNA Sequencing 221

9.3 The Human Genome Project (HGP) 222

9.4 Liquid Phase Chromatography 223

9.5 Polymerase Chain Reaction (PCR) 223

10. New Cancer Markers in Basic Research 232

10.1 Genetics of Cancer 232

10.2 Telomerase 235

10.3 Stomach Cancer 237

10.4 Head and Neck Cancer 238

10.5 Breast Cancer 239

Aarkstore Enterprise     cancer     diagnostic testing     oncology